CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2011-05-28
REPLACES  Medication use and seniors
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2012-12-08

TOPICS
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

CMA POLICY

Cannabis for Medical Purposes

Guidelines:

The Canadian Medical Association (CMA) recognizes the varied requirements of those individuals suffering from terminal illnesses or chronic diseases for which conventional therapies have not been effective and for whom cannabinoids might provide relief.

However, there are many concerns, generally related to the lack of data to support the use of cannabis, its short supply for medical purposes, and the need for further research.

Cannabis products may be used to treat conditions for which there is a lack of data and should be used with caution. The CMA recommends the development of a comprehensive cannabis policy that includes research, regulation, and education.

Documents

Health Canada consultation on edible cannabis, extracts & topicals

CMA Policybase - Canadian Medical Association
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

PRIORITY
Response to consultation

DATE
2018-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
### Implementation of National Pharmacare

[https://policybase.cma.ca/link/policy13933](https://policybase.cma.ca/link/policy13933)

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-10-02</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

![CMA submission: IMPLEMENTATION OF NATIONAL PHARMACARE](image)

Submission to the Advisory Council

Review by: 2019
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/link/policy13931

POLICY TYPE
Policy endorsement

DATE
2018-08-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE: Response to consultation
DATE: 2018-07-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

The Canadian Medical Association has the opportunity to participate in the consultation on front-of-package labelling through its involvement in the policy development process. The purpose of this response is to address key points of the consultation and offer recommendations.

The Canadian Medical Association (CMA) is a national, bilingual and medical organization representing physicians, medical students, and allied health professionals. The CMA is a leader in advocating for the health of Canadians and for a medical system that is second to none.

The CMA recommends that the proposed legislation include clear and concise labeling that is easy to read and understand. This will help consumers make informed decisions about the products they choose to purchase. The labeling should be standardized across all products to ensure consistency and transparency.

The CMA encourages the federal government to consider incorporating health information, such as nutritional content, into the labeling process. This will provide consumers with additional information to make informed choices about their health and well-being.

The CMA supports the development of a comprehensive plan for the implementation and enforcement of the labeling requirements. This plan should include clear guidelines for manufacturers and retailers to ensure compliance with the new labeling standards.

The CMA recommends that the government provide additional resources for health promotion and education programs to help consumers understand the importance of reading labels and make informed choices about their health and well-being.

The CMA encourages the federal government to consider the feedback provided during the consultation process and to work collaboratively with stakeholders to develop and implement effective labeling policies.
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE
Parliamentary submission

DATE
2018-04-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE        Response to consultation
DATE               2018-01-19
TOPICS             Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE
Response to consultation

DATE
2017-12-07

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products
Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017